Short answer: brand-name Vyleesi, a hypothetical generic, and compounded "PT-141" sit in three different FDA tiers — NDA, ANDA, and pharmacy compounding — and they are not interchangeable.
There are actually three different regulatory categories a bremelanotide product could fall into — brand-name, generic, and compounded — and they're genuinely not interchangeable. Here's how each pathway actually works, and where compounded "PT-141" products fit into that picture.
Tier 1: Brand-Name Vyleesi, Reviewed Through a Full NDA
The FDA approved Vyleesi (bremelanotide) through New Drug Application (NDA) 210557 on June 21, 2019, for acquired, generalized HSDD in premenopausal women.[1]An NDA is the pathway for an entirely new drug — the FDA reviews whether it's safe and effective for the proposed use, whether benefits outweigh risks, whether the labeling is appropriate, and whether manufacturing methods and quality controls actually preserve the product's identity, strength, quality, and purity.[4] That approval applies to a specific, defined product: bremelanotide 1.75 mg/0.3 mL in a single-dose, prefilled autoinjector, with the label instructing injection into the abdomen or thigh at least 45 minutes before anticipated activity.[3] The label also limits use to one dose per 24 hours, no more than eight per month, and directs discontinuation after eight weeks without improvement — all specific, FDA-reviewed instructions tied to this exact product.[3]
Tier 2: Generic Bremelanotide, Reviewed Through an ANDA
A generic is a different thing from a compounded product, even though both can sound similar in casual conversation. A generic manufacturer submits an Abbreviated New Drug Application (ANDA) and has to demonstrate its product is comparable to the reference drug in dosage form, strength, route, quality, performance, and intended use.[5] To get an ANDA approved, the FDA generally requires bioequivalence evidence — the generic has to deliver the same amount of active ingredient into the bloodstream in the same timeframe as the reference product. Approved generics are themselves FDA-approved medicines, not custom-compounded preparations.[5]
Tier 3: Compounded "PT-141," Made Under a Prescription
A pharmacy-compounded bremelanotide product is neither Vyleesi nor an FDA-approved generic, just because it contains bremelanotide or gets marketed as "PT-141." Compounded means the preparation was made for a specific prescription rather than manufactured under an approved NDA or ANDA.[2] Traditional compounding under Section 503A generally involves a licensed pharmacist in a state-licensed pharmacy — or a physician — compounding for a specific, identified patient based on a valid prescription, subject to statutory conditions. State pharmacy boards generally handle day-to-day oversight of these pharmacies.[2]
Why this variation actually matters clinically: compounded bremelanotide can differ from Vyleesi in concentration, inactive ingredients, administration route, injection device, packaging, and instructions. That means it shouldn't automatically be assumed to match the FDA-approved autoinjector's dose delivery, absorption, effectiveness, or safety profile.[2]The FDA doesn't verify a compounded drug's safety, effectiveness, or quality before it's marketed — that doesn't mean every compounded medication is defective, but it does mean it hasn't gone through the same product-specific review supporting the Vyleesi label.[2]
The Regulatory Wrinkle Specific to Bremelanotide
Section 503A restricts compounding products that are "essentially copies" of something already commercially available. FDA guidance is explicit that a compounder relying on 503A's exemptions generally shouldn't regularly or in large amounts compound a drug that's essentially a copy of a commercially available one.[6]Since Vyleesi already exists as an FDA-approved commercial product, this rule is directly relevant to compounded bremelanotide specifically. Whether a given compounded prescription is actually appropriate or permitted comes down to real facts: whether Vyleesi is genuinely available and suitable, whether there's a documented clinical difference for that specific patient, the exact formulation and route used, state pharmacy law, and whether the compounder is actually meeting federal requirements.[6] Compounding does have a real role when an FDA-approved product genuinely isn't appropriate — an allergy to an inactive ingredient, or a dosage form that isn't commercially available — but it shouldn't be framed as a routine substitute just because a product markets itself as "custom" or "better." [2]
Two Terms That Get Blurred Together, but Shouldn't Be
"Off-label" and "compounded" describe genuinely different things. Off-label prescribing means using an FDA-approved drug outside its approved label — like prescribing Vyleesi to a population it's not approved for. Compounding means the product itself, regardless of intended use, was never FDA-approved as a finished drug in the first place.[2]A compounded bremelanotide formulation has non-FDA-approved status no matter who it's prescribed to or why — that's a different category from off-label use of an actually-approved product.[2]
What Honest Disclosure Looks Like
If a provider recommends compounded bremelanotide, the rationale should be documented and transparent: the specific clinical reason Vyleesi isn't suitable, the identity of the compounding pharmacy, the exact formulation and administration route, and a plain statement that the product is compounded and not FDA-approved.[2]A service shouldn't blur these lines with language like "brand-equivalent," "same as Vyleesi," or "FDA-approved PT-141" for a compounded product — you deserve to know the actual product name, route, dose, pharmacy identity, regulatory status, expected benefits, risks, and follow-up plan before deciding.[2]
The Bottom Line
The practical comparison is straightforward once the tiers are laid out: Vyleesi is an FDA-approved, standardized autoinjector for a specific HSDD diagnosis. Compounded bremelanotide is a patient-specific, non-FDA-approved preparation that can have a legitimate, limited clinical role — but it's not interchangeable with the branded product. The right choice should follow a full HSDD evaluation, cardiovascular screening, and an honest conversation about where your medication is actually coming from.[3]
Worth asking any provider directly which tier they're prescribing from, and if compounded, why Vyleesi specifically wasn't the recommended option for you.
Sources
- Vyleesi (Bremelanotide) Subcutaneous Injection: FDA Approval Letter — U.S. Food and Drug Administration accessdata.fda.gov
- Compounding and the FDA: Questions and Answers — U.S. Food and Drug Administration fda.gov
- Vyleesi (Bremelanotide) Prescribing Information — U.S. Food and Drug Administration accessdata.fda.gov
- New Drug Application (NDA) — U.S. Food and Drug Administration fda.gov
- Abbreviated New Drug Application (ANDA) — U.S. Food and Drug Administration fda.gov
- Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act — U.S. Food and Drug Administration fda.gov
Frequently Asked Questions
Is there a generic version of Vyleesi?
Whether a generic exists depends on current patent and exclusivity status — but any real generic would go through FDA's ANDA process and bioequivalence review, which is a different pathway entirely from pharmacy compounding.[5]
Can a compounding pharmacy legally make bremelanotide since Vyleesi already exists?
It depends on the specific facts — Section 503A restricts compounding something that's "essentially a copy" of an already-approved product, so permissibility hinges on documented clinical need, formulation differences, and compliance with federal and state requirements.[6]
Is "off-label" the same as "compounded"?
No — off-label means using an FDA-approved drug outside its approved indication. Compounded means the product itself was never FDA-approved as a finished drug, regardless of how it's used.[2]
What should a provider disclose if they prescribe compounded bremelanotide?
The clinical reason Vyleesi wasn't used, the compounding pharmacy's identity, the exact formulation and route, and a clear statement that it's compounded rather than FDA-approved.[2]